Desarrollo y validación de un modelo experimental de encefalopatía hepática en ratas con ascitis. Efectos de la administración de IGF-1 frente a rifaximina en este modelo experimental

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Unknown venue

• Publication date

  2008-07-03

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Insulin-like Growth Factors

  2024cited by this paper
• Effect of insulin-like growth factor I on in vivo intestinal absorption of D-galactose in cirrhotic rats.

  2017cited by this paper
• Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin.

  2008cited by this paper
• In vivo1H magnetic resonance spectroscopy‐derived metabolite variations between acute‐on‐chronic liver failure and acute liver failure

  2008cited by this paper
• Hospitalizations During the Use of Rifaximin Versus Lactulose for the Treatment of Hepatic Encephalopathy

  2007cited by this paper
• [Insulin-like growth factor I (IGF-I) and liver cirrhosis].

  2007cited by this paper
• Neuronal cell death in hepatic encephalopathy

  2007cited by this paper
• Glutamate‐induced activation of nitric oxide synthase is impaired in cerebral cortex in vivo in rats with chronic liver failure

  2007cited by this paper
• [Hepatic stellate cells and oxidative stress].

  2007cited by this paper
• NMDA receptors in hyperammonemia and hepatic encephalopathy

  2007cited by this paper
• Hepatic encephalopathy: pathophysiology and advances in therapy.

  2007cited by this paper
• Células estrelladas hepáticas y estrés oxidativo

  2007cited by this paper
• Tablas de normalidad de la población española para los tests psicométricos utilizados en el diagnóstico de la encefalopatía hepática mínima

  2006cited by this paper
• Pathogenetic interplay between osmotic and oxidative stress: the hepatic encephalopathy paradigm

  2006cited by this paper
• Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial (final report Maag Lever Darm Stichting projectno. WS 00???78 (WS 97/87))

  2006cited by this paper
• Current and future applications of magnetic resonance imaging and spectroscopy of the brain in hepatic encephalopathy.

  2006cited by this paper
• [Normality tables in the Spanish population for psychometric tests used in the diagnosis of minimal hepatic encephalopathy].

  2006cited by this paper
• Inflammation and brain edema: new insights into the role of chemokines and their receptors.

  2006cited by this paper
• [Development of blood vessels of the greater omentum in the hepatic lobe after vascular ligation. An experimental model in the rats].

  2006cited by this paper
• Brain edema and inflammatory activation in bile duct ligated rats with diet‐induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis

  2006cited by this paper
• Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats

  2006cited by this paper
• Hepatic encephalopathy: A review of its pathophysiology and treatment

  2006cited by this paper
• Contribution of altered signal transduction associated to glutamate receptors in brain to the neurological alterations of hepatic encephalopathy.

  2006cited by this paper
• Glutamine: A Trojan horse in ammonia neurotoxicity

  2006cited by this paper
• Evaluation of plasma ammonia levels in patients with acute liver failure and chronic liver disease and its correlation with the severity of hepatic encephalopathy and clinical features of raised intracranial tension.

  2005cited by this paper
• Neurological and neuropsychiatric syndromes associated with liver disease.

  2005cited by this paper
• Dispelling the Myths in the treatment of Hepatic Encephalopathy

  2005cited by this paper
• Small Bowel Bacterial Overgrowth Patients with Alcoholic Cirrhosis in

  2005cited by this paper
• Progressive hepatocytic fatty infiltration in rats with prehepatic portal hypertension.

  2005cited by this paper
• Antioxidant effects of insulin-like growth factor-I (IGF-I) in rats with advanced liver cirrhosis

  2005cited by this paper
• Hyperammonemia, brain edema and blood-brain barrier alterations in prehepatic portal hypertensive rats and paracetamol intoxication.

  2004cited by this paper
• Correlation Between Ammonia Levels and the Severity of Hepatic Encephalopathy

  2004cited by this paper
• Jejunal microvilli atrophy and reduced nutrient transport in rats with advanced liver cirrhosis: improvement by Insulin-like Growth Factor I

  2004cited by this paper
• Bone mineral density among cirrhotic patients awaiting liver transplantation

  2004cited by this paper
• Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials

  2004cited by this paper
• Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy

  2004cited by this paper
• Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy.

  2004cited by this paper
• Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy.

  2004cited by this paper
• Increased brain serotonin turnover correlates with the degree of shunting and hyperammonemia in rats following variable portal vein stenosis.

  2004cited by this paper
• Introducción a la farmacología del sistema nervioso central. Neurotransmisores y receptores

  2004cited by this paper
• Blood Ammonia Levels and Hepatic Encephalopathy

  2004cited by this paper
• Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.

  2003cited by this paper
• T2 hyperintensity along the cortico‐spinal tract in cirrhosis relates to functional abnormalities

  2003cited by this paper
• The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis

  2003cited by this paper
• Neuropsychological impairment in patients with chronic hepatitis C

  2002cited by this paper
• Ecoendoscopia en el diagnóstico de extensión de las neoplasias digestivas

  2002cited by this paper
• Magnetic resonance imaging measurement of brain edema in patients with liver disease: resolution after transplantation

  2002cited by this paper
• Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta‐analysis

  2002cited by this paper
• 1H Magnetic Resonance in the Study of Hepatic Encephalopathy in Humans

  2002cited by this paper
• Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS

  2002cited by this paper
• Understanding the mechanisms of cerebral complications in fulminant hepatic failure: fluxes better than levels.

  2002cited by this paper
• Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy

  2001cited by this paper
• Effects of zinc deficiency/zinc supplementation on ammonia metabolism in patients with decompensated liver cirrhosis.

  2001cited by this paper
• The development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1)H-magnetic resonance abnormalities after liver transplantation.

  2001cited by this paper
• Antifibrogenic effect in vivo of low doses of insulin-like growth factor-I in cirrhotic rats.

  2001cited by this paper
• Improvement of magnetic resonance spectroscopic abnormalities but not pallidal hyperintensity followed amelioration of hepatic encephalopathy after occlusion of a large spleno-renal shunt.

  2001cited by this paper
• Intrahepatic amino acid and glucose metabolism in a D‐galactosamine–induced rat liver failure model

  2001cited by this paper
• Neuropsychological characterization of hepatic encephalopathy.

  2001cited by this paper
• Evidence for a cerebral effect of the hepatitis C virus.

  2001cited by this paper
• Altered intestinal transport of amino acids in cirrhotic rats: the effect of insulin-like growth factor-I.

  2000cited by this paper
• Tratamiento de la encefalopatía hepática. Fármacos y mecanismos de acción

  2000cited by this paper
• Insulin‐like growth factor‐I reverts testicular atrophy in rats with advanced cirrhosis

  2000cited by this paper
• Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double‐blind, randomized, dose‐finding multi‐centre study

  2000cited by this paper
• Establishment of an animal model of hepatic encephalopathy.

  2000cited by this paper
• Encefalopatía hepática. patogenia y formas clínicas

  2000cited by this paper
• Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?

  2000cited by this paper
• Complications of cirrhosis III. Hepatic encephalopathy.

  2000cited by this paper
• Effect of lactitol on blood ammonia response to oral glutamine challenge in cirrhotic patients: evidence for an effect of nonabsorbable disaccharides on small intestine ammonia generation

  1999cited by this paper
• The role of glutaminase in the small intestine.

  1999cited by this paper
• Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction.

  1999cited by this paper
• Azoxymethane-induced fulminant hepatic failure in C57BL/6J mice: characterization of a new animal model.

  1999cited by this paper
• Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.

  1998cited by this paper
• Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: An italian multicenter double‐blind, placebo‐controlled, cross‐over study

  1998cited by this paper
• Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment.

  1998cited by this paper
• Insulin-like growth factor 1 (IGF-1) in liver cirrhosis: a marker of hepatocellular dysfunction?

  1998cited by this paper
• Bone mineral density, serum insulin‐like growth factor I, and bone turnover markers in viral cirrhosis

  1998cited by this paper
• Stenosis of a portacaval anastomosis affects circadian locomotor activity in the rat: a multivariable analysis.

  1997cited by this paper
• Impaired intestinal sugar transport in cirrhotic rats: correction by low doses of insulin-like growth factor I.

  1997cited by this paper
• Nutritional and prognostic significance of insulin-like growth factor 1 in patients with liver cirrhosis.

  1997cited by this paper
• Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors.

  1997cited by this paper
• Effects of insulin-like growth factor I on glucose metabolism in rats with liver cirrhosis.

  1997cited by this paper
• Ammonia and GABA‐ergic neurotransmission: Interrelated factors in the pathogenesis of hepatic encephalopathy

  1997cited by this paper
• Low doses of insulin-like growth factor-I improve nitrogen retention and food efficiency in rats with early cirrhosis.

  1997cited by this paper
• Role of bacterial adherence and the mucus barrier on bacterial translocation: effects of protein malnutrition and endotoxin in rats.

  1997cited by this paper
• Spontaneous Bacterial Peritonitis

  1997cited by this paper
• Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites.

  1997cited by this paper
• Therapeutic efficacy of L‐ornithine‐L‐aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo‐controlled, double‐blind study

  1997cited by this paper
• Oral glutamine challenge in cirrhotics pre‐ and post‐liver transplantation: A psychometric and analyzed EEG study

  1997cited by this paper
• Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation.

  1997cited by this paper
• Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis.

  1997cited by this paper
• Insulin-like growth factor I is an independent coregulatory modulator of natural killer (NK) cell activity.

  1996cited by this paper
• The regulation of L-proline transport by insulin-like growth factor-I in human osteoblast-like SaOS-2 cells

  1996cited by this paper
• Zinc supplementation and amino acid‐nitrogen metabolism in patients with advanced cirrhosis

  1996cited by this paper
• Prognostic value of insulinlike growth factor I and its binding protein in patients with alcohol‐induced liver disease

  1996cited by this paper
• Increased blood manganese in cirrhotic patients: Relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms

  1996cited by this paper
• pathogenesis and treatment of chronic hepatic encephalopathy

  1996cited by this paper
• Modulation of ligand binding to components of the GABAA receptor complex by ammonia: implications for the pathogenesis of hyperammonemic syndromes.

  1996cited by this paper
• Cholecystokinin increases small intestinal motility and reduces enteric bacterial overgrowth and translocation in rats with surgically induced acute liver failure.

  1996cited by this paper
• Glutamine, myo‐inositol, and organic brain osmolytes after portocaval anastomosis in the rat: Implications for ammonia‐induced brain edema

  1996cited by this paper
• Review article: pathogenesis and treatment of chronic hepatic encephalopathy.

  1996cited by this paper

• Magnetic Resonance and Spectroscopy in the hepatic encephalopathy

  2014cites this paper